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120 Anti-Pseudomonas aeruginosa IgY antibodies promote bacterial
clearance in a murine pneumonia model
K. Thomsen1, L. Christophersen1, C. Moser1, P.Ø. Jensen1, T. Bjarnsholt1,
N. Høiby1. 1Rigshospitalet, Department of Clinical Microbiology, Copenhagen,
Denmark
Objectives: The present study explored the possible protective effect of IgY on PA
lung infection in vivo.
Methods: In vivo model of acute lung infection: Balb/c mice were anaesthetized
with isoﬂurane and PAO1 vaccine strain ± speciﬁc (S-IgY) or control (C-IgY) was
inoculated intranasally. Mice were sacriﬁced after 2, 6 and 24h and lungs removed
aseptically, weighted and suspended in PBS. A blinded observer engaged a clinical
scoring system (0−5) of the mice. Lungs were homogenized, serially diluted and
cultured on Conradi-Drigalski medium for estimation of bacterial load.
Results: Relative lung weight: Lung weights in the S-IgY treated group were
signiﬁcantly reduced 24h post-infection compared to PBS controls (p< 0.03). No
signiﬁcant difference between C-IgY and PBS groups were observed.
Clinical symptom score: The clinical score was signiﬁcantly lower in the S-IgY
group compared to controls after 6h (C-IgY: p< 0.05, PBS: p< 0.05). After 24h
the clinical score in the S-IgY was reduced additionally compared to controls
(PBS: p< 0.002, C-IgY: p< 0.04). No signiﬁcant difference between C-IgY and
PBS groups were observed.
Quantitative bacteriology: The bacterial load of S-IgY treated mice was signiﬁcantly
reduced 2h post-infection compared to PBS group (p< 0.02) and C-IgY (p< 0.03)
and further reduced 6h post-infection compared to both control groups (PBS:
p< 0.0001, C-IgY: p< 0.03). After 24h the lung bacteriology in S-IgY treated
mice was reduced by 2 logs compared to PBS (p< 0.0001) and C-IgY (p< 0.0002)
groups.
Conclusion: The present results imply that anti-PA IgY antibodies protects against
PA lung infection due to readily bacterial clearance in the airways.
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Objectives: P. aeruginosa (Pa) lung infections cause a lung function decline and
a systemic increase of serum antibodies against Pa antigens. Eradication treatment
can clear Pa in the early phases of the infection. The purpose of this study was to
evaluate, as marker of early stages of Pa infection, the anti-Pa immune response in
not chronically infected patients.
Methods: Serum from 153 not chronically infected patients (median age 10 years,
range 0−46) in a regular follow-up in the period 2011–2013 were analyzed using
Enzyme-Linked Immuno Sorbent Assay (ELISA) for the presence of IgG antibodies
against Pa sonicated cell extract (St-Ag) (serogroups 1−17). Patients were classiﬁed
according to their microbiological status (Leeds deﬁnition).
Results: During the observation period 2 (1.3%) patients became chronically
infected. Patients never infected or free from Pa were respectively 48 (31.4%) and
60 (39.2%) of the total. In both groups antibody titre was under the cut-off level
(1.50±1.90 EU). In the group of 43 (28.1%) patients, intermittently infected by
Pa, the titer of anti-Pa antibodies was signiﬁcantly higher in subjects presenting
a concomitant bacterial isolation than those who did not showed Pa isolation
(3.03 EU ± SD 3.20, 1.72 EU ± SD 1.7, respectively) (P< 0.05).
Conclusion: The evaluation of speciﬁc anti-Pa antibodies may be a useful way to
monitor early Pa infection in patients with intermittent infection.
122 Modulation of cystic ﬁbrosis gut inﬂammation − a pivotal role of
the lung gut axis?
G. O’Callaghan1,2, N. Ronan1, A. Houston3,4, F. Shanahan3,4, B.J. Plant1,2.
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Objectives: Recent studies have suggested a potential role for the lung-gut axis
in the pathogenesis of gut inﬂammation in CF. Modulating lung inﬂammation
by targeting the cycloxygenase pathway and prostaglandin E2 (PGE2) can slow
inﬂammatory pulmonary responses in people with CF. The objective of this study
is to investigate if pro-inﬂammatory changes in the lung affect gut inﬂammation.
Methods: Plasma levels of PGE2 in CF patients (n = 25) was detected. CF bronchial
epithelial cells (DF508 homozygote, CFBE41o−) and human bronchial epithelial
cells (16HBEo−) were seeded at 2×105 cells/ml. Cells were stimulated with PGE2
and cell supernatant was harvested. HT29 colon epithelial cells were seeded at
2×105 cells/ml and treated with harvested supernatant. Cell proliferation of HT29
cells was determined and changes in cytokine levels of IL-6, IL-8 and TNFa were
detected by ELISA.
Results: Supernatant from CF lung cells augmented IL-6, IL-8 and TNFa produc-
tion by HT29 cells. Relative to HT29 cells cultured in normal bronchial 16HBEo−
epithelial cells, secretion of IL-6, IL-8 and TNFa by HT29 cells incubated with
CFBE41o− CF cell supernatant was signiﬁcantly increased 2.7 fold, 1.8 fold and 1.4
fold respectively. Culture of the cells in PGE2-treated CF cell supernatant relative
to PGE2-treated normal bronchial epithelial cells further increased IL-6, IL-8 and
TNFa. There was no signiﬁcant change in cell proliferation of HT29 intestinal
epithelium cells.
Conclusion: This study shows that inﬂammatory changes in the CF lung can
modulate cytokine production in the gut. Thus, independent of active CF lung
infection this mechanism may regulate intestinal inﬂammation.
123 How frequent is Clostridium in our CF patients?
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Objectives: Children with cystic ﬁbrosis are, unfortunately, candidates at multiple
antibiotic courses, having a potential increase risk for pseudomembranous colitis
with Clostridium difﬁcile. The aim of the paper was to evaluate the frequency of
C. difﬁcile infection among children with cystic ﬁbrosis (CF).
Methods: Retrospective analysis over a ten years period was done, using the
information from our CF center’s database. In all the patients, only presentation with
diarrhea occurred during antibiotherapy were taken into consideration. Diagnosis
test for C. difﬁcile infection was performed by enzyme immunoassay for detection
of toxins A and B.
Results: Over a ten years period, 308 patients with cystic ﬁbrosis were admitted
in our clinic; only ﬁve of them (1.62%) were diagnosed with C. difﬁcile infection.
Patients were diagnosed in the last 4 years, by the detection e of toxin A or toxin
A and B (in 2 patients) in the presence of diarrhea; they had a favorable outcome,
with a good response to treatment (metronidazole in 3 cases, metronidazole and
vancomycin in 2 cases). All patients had chronic Pseudomonas aeruginosa infection
and received more than fourteen days of antibiotics.
Conclusion: Clostridium difﬁcile infection should be consider for evaluation in
cystic ﬁbrosis patients with diarrhea who receive antibiotics. Special attention is
necessary when antibiotherapy is given for a long time, as commonly reccomended
in cystic ﬁbrosis patients.
